High-end pharmaceutical equipment has become a new driving force for the growth of pharmaceutical machine companies!

In recent years, driven by a series of policies, the growth of China's pharmaceutical industry has become stronger and stronger
.
Affected by this, the pharmaceutical equipment industry as an upstream industry has also started an accelerated development model
.
Among them, it is worth mentioning that, in the context of the continuous expansion of the domestic pharmaceutical equipment industry and the relatively complete product range, in order to meet the rising demand of pharmaceutical companies and increase the breakthrough of their own performance, many pharmaceutical equipment companies have Begin to accelerate its march into the high-end market
.
The new driving force for the growth of high-end pharmaceutical equipment and pharmaceutical machine companies (picture source: Pharmaceutical Network) It is understood that Chutian Technology is one of China's very active companies in entering the high-end pharmaceutical equipment market
.
At present, its fields have spanned biological medicines, bulk medicines, Chinese patent medicines, chemical medicines, etc.
, and its products have also covered many categories such as liquid medicine equipment, solid preparation equipment, powder medicine equipment and so on
.
According to its semi-annual report, Chutian Technology has been able to provide a variety of highly intelligent, cost-effective biopharmaceutical equipment
.
Thanks to its outstanding performance in high-end pharmaceutical equipment, the planned production capacity of domestic vaccine companies such as Kexing, Sinopharm, and Cansino is close to 9 billion doses.
It is in the background of active expansion.
Chutian Technology As one of the few domestic companies that can provide high-end vaccine production equipment, it has obtained a large number of orders from head vaccine companies with its complete product categories and high quality
.
In addition to achieving breakthrough growth in performance, its company's market influence has also been further improved
.
It is worth noting that for the future, Chutian Technology has made it clear that it will continue to implement the development strategy of "one vertical, one horizontal and one platform", give play to the synergies of various subsidiaries, increase investment in R&D and advanced manufacturing technology, and actively grasp AI and Market opportunities for intelligent equipment, and steadily promote the construction of production capacity, and strive to achieve the strategic goal of reaching 20 billion yuan in sales in 2030
.
Of course, in addition to Chutian Technology, many companies are also accelerating their entry into the high-end market
.
For example, Canaan Technology plans to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems, and pharmaceutical R&D service areas for bio-innovative drugs.

.
In addition, Tofflon also stated in an earlier survey that the company will provide global customers with forward-looking and competitive pharmaceutical equipment, food equipment, Systematic solutions such as equipment in the field of cell therapy
.
Judging from the fact that many pharmaceutical equipment companies are making efforts to build higher-end pharmaceutical equipment, and in this context, the performance has begun to improve, the overall business model of the domestic pharmaceutical equipment industry is continuously upgrading; at the same time, the competitiveness in the high-end market is also increasing.
Constantly improve
.
The industry believes that under this trend, through the continuous development and innovation of pharmaceutical machinery companies in the future, domestic pharmaceutical equipment companies will gradually become a subdivision of high-end manufacturing in China, and their performance will continue to grow; in addition, the industry will gradually fade away.
Properties usher in long-term growth
.
However, it should be noted that although high-end pharmaceutical equipment has become a new driving force for the growth of pharmaceutical machine companies, problems such as insufficient domestic high-end equipment and lack of high-tech content still exist
.
The industry pointed out that in this context, relevant companies need to continue to break through the core technology bottlenecks and improve R&D and design capabilities to grasp the industry’s "pulse
.
" Moreover, in addition to continuous efforts in product technology and quality, pharmaceutical machinery companies also need to strengthen the information construction of pharmaceutical equipment management and maintenance by vigorously training professional talents, and establish effective management work models to meet the needs of pharmaceutical companies.
More demand for high-end equipment, and further improve the safety of clinical medication
.